While Bio-Rad Laboratories Inc has underperformed by -0.60%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BIO rose by 12.59%, with highs and lows ranging from $387.99 to $262.12, whereas the simple moving average jumped by 7.91% in the last 200 days.
On October 01, 2024, Citigroup Upgraded Bio-Rad Laboratories Inc (NYSE: BIO) to Buy. A report published by Wells Fargo on August 28, 2024, Initiated its previous ‘Equal Weight’ rating for BIO. Jefferies also rated BIO shares as ‘Hold’, setting a target price of $315 on the company’s shares in an initiating report dated June 03, 2024. Citigroup April 03, 2024d the rating to Neutral on April 03, 2024, and set its price target from $400 to $365. UBS initiated its ‘Buy’ rating for BIO, as published in its report on December 07, 2023. Wells Fargo’s report from June 16, 2023 suggests a price prediction of $550 for BIO shares, giving the stock a ‘Overweight’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of Bio-Rad Laboratories Inc (BIO)
Further, the quarter-over-quarter increase in sales is 2.79%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Bio-Rad Laboratories Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -9.79% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.52, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and BIO is recording an average volume of 185.64K. On a monthly basis, the volatility of the stock is set at 3.00%, whereas on a weekly basis, it is put at 3.52%, with a gain of 0.19% over the past seven days. Furthermore, long-term investors anticipate a median target price of $399.33, showing growth from the present price of $342.41, which can serve as yet another indication of whether BIO is worth investing in or should be passed over.
How Do You Analyze Bio-Rad Laboratories Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 31.52%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 68.61% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BIO shares are owned by institutional investors to the tune of 68.61% at present.
